1. A case series on the role of 18F-FDG PET/CT-guided biopsy of osseous metastases
- Author
-
Michael Farrell, Gina Hyun, Michael P. Goold, and Pavel Krapiva
- Subjects
lcsh:Medical physics. Medical radiology. Nuclear medicine ,Core needle ,medicine.medical_specialty ,PET/CT ,lcsh:R895-920 ,Biophysics ,030204 cardiovascular system & hematology ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Biopsy ,Computer Science (miscellaneous) ,medicine ,Radiology, Nuclear Medicine and imaging ,Sampling (medicine) ,In patient ,PET-CT ,Bone biopsy ,medicine.diagnostic_test ,business.industry ,Secondary Malignancy ,Positron emission tomography ,Osseous metastases ,Molecular Medicine ,Fdg pet ct ,Original Article ,Radiology ,business - Abstract
Purpose This case series explores the utility of positron emission tomography (PET)/computed tomography (CT) guidance for biopsy of 18F-fludeoxyglucose (FDG)-avid osseous lesions that are inconspicuous on CT. Methods PET/CT-guided core biopsies were performed in four patients with suspected malignancies given 18F-FDG-avid osseous lesions that were inconspicuous on CT alone. The final diagnosis for each patient was determined by histopathological and molecular testing. Results PET/CT-guided biopsy yielded accurate sampling via core needle biopsy (CNB) with histopathological confirmation of osseous metastases of the primary malignancy as opposed to a secondary malignancy in three patients and ruled-out metastatic spread in the fourth. Conclusion PET/CT-guided biopsy of hypermetabolic osseous lesions that are inconspicuous on CT alone is an effective and safe diagnostic tool in patients with suspected malignancy.
- Published
- 2021